Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company known for its innovative medicines in HIV, hepatitis, and oncology, has been the subject of recent analyst scrutiny.

Insights speaks directly to the people with an inside track on the big issues. Here, Dan Glass demands pharmaceutical company ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company known for its innovative medicines in HIV, hepatitis, and oncology, has been the subject of recent analyst scrutiny. As the ...